MNPR Latest Press Releases

-- November 12, 2026 --

Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates Globe Newswire 8:00 AM

-- November 9, 2026 --

Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD - The Liver Meeting 2026 Globe Newswire 8:00 AM

-- November 2, 2026 --

Monopar to Present at AASLD - The Liver Meeting 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data Globe Newswire 8:00 AM

-- August 19, 2026 --

Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD - The Liver Meeting 2026 Globe Newswire 8:00 AM

-- August 12, 2026 --

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Globe Newswire 9:30 AM

-- July 22, 2026 --

Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease Globe Newswire 8:00 AM

-- July 20, 2026 --

Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team Globe Newswire 8:00 AM

-- June 30, 2026 --

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease Globe Newswire 8:00 AM

-- June 26, 2026 --

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease Globe Newswire 4:05 PM

Market Data Delayed 15 Minutes